{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"50"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"65"}],"units":"Participants"}],"groups":[{"description":"Treosulfan IV over 2 hours on days -6 to -4 and fludarabine phosphate IV over 30 minutes on days -6 to -2.","id":"OG000","title":"Arm A (Treosulfan, Fludarabine Phosphate)"},{"description":"Treosulfan and fludarabine phosphate as in Arm A and undergo low-dose TBI on day 0.","id":"OG001","title":"Arm B (Treosulfan, Fludarabine Phosphate, TBI)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 84 days","title":"Number of Participants With Acute GVHD, Graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0","type":"SECONDARY","unitOfMeasure":"Participants"}